Erlotinib plus ramucirumab (RAM) as first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation: phase 1B safety results and Phase 3 design of the ongoing Phase 1B/3 study RELAY

被引：0
|
作者：
Bischoff, H. [1 ]
Garon, E. B. [2 ]
Lee, P. [3 ]
He, S. [4 ]
Kropf-Sanchen, C. [5 ]
Kimmich, M. [6 ]
Nakagawa, K. [7 ]
Reck, M. [8 ]
机构：
[1] Univ Klinikum Heidelberg, Thoraxklin, Onkol Thoraxtumoren, Heidelberg, Germany
[2] Univ Calif Los Angeles, Med Ctr, Santa Monica, CA USA
[3] Eli Lilly & Co, Bridgewater, MA USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Univ Klinikum Ulm, Sekt Pneumol, Innere Med 2, Ulm, Germany
[6] Robert Bosch Krankenhaus, Klin Schillerhohe, Pneumol & Pneumol Onkol, Gerlingen, Germany
[7] Kinki Univ, Sch Med, Osaka, Japan
[8] German Ctr Lung Res DZL, LungenClin Grosshansdorf, ARCN, Grosshansdorf, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P593
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [1] Randomized phase 1b/3 study of erlotinib plus ramucirumab in first-line EGFR mut 1 stage IV NSCLC: phase 1b safety results
    Nakagawa, K.
    Garon, E. B.
    Paz-Ares, L.
    Ponce, S.
    Corral Jaime, J.
    Juan Vidal, O.
    Nadal, E.
    Kiura, K.
    He, S.
    Treat, J.
    Dalal, R.
    Lee, P.
    Reck, M.
    Novello, S.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [2] Randomized Phase 1b/3 Study of Erlotinib plus Ramucirumab in Untreated EGFR Mutation-Positive Stage IV NSCLC: Phase 1b Outcomes
    Nakagawa, K.
    Garon, E.
    Paz-Ares, L.
    Ponce, S.
    Corral Jaime, J.
    Juan Vidal, O.
    Nadal, E.
    Kiura, K.
    Park, K.
    Widau, R.
    Alexandris, E.
    He, S.
    Lee, P.
    Reck, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2228 - S2229
  • [3] VeriStrat® and Epidermal Growth Factor Receptor Mutation Status in a Phase 1b/2 Study of Cabozantinib plus /- Erlotinib in Non-Small Cell Lung Cancer
    Padda, Sukhmani K.
    Lara, Primo, Jr.
    Gettinger, Scott N.
    Engelman, Jeffrey A.
    Jaenne, Pasi A.
    West, Howard
    Zhou, Lisa Y.
    Subramaniam, Deepa S.
    Leach, Joseph W.
    Wax, Michael B.
    Neal, Joel W.
    Clary, Douglas O.
    Goodman, Laurie J.
    Wakelee, Heather A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S291 - S291
  • [4] Randomized Phase 1 b/3 Study of Erlotinib plus Ramucirumab in First -Line EGFR Mut plus Stage IV NSCLC: Phase 1 b Safety Results
    Nakagawa, Kazuhiko
    Paz-Ares, Luis
    Ponce, Santiago
    Corral, Jesus
    Vidal, Oscar
    Nadal, Ernest
    Kiura, Katsuyuki
    Liu, Jingyi
    He, Shuang
    Treat, Joseph
    Dalal, Rita
    Lee, Pablo
    Reck, Martin
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S285 - S285
  • [5] Phase 1b study of capecitabine and erlotinib in advanced non-small cell lung cancer
    Lu, S.
    Popat, S.
    Puglisi, M.
    Kaudeer, N.
    Gennatas, S.
    Hewish, M.
    Ayite, B.
    Bhosle, J.
    O'Brien, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S828 - S828
  • [6] Results of a phase 1b study of osimertinib plus sapanisertib or alisertib for osimertinibresistant, EGFR-mutant non-small cell lung cancer (NSCLC).
    Elamin, Yasir Y.
    Negrao, Marcelo Vailati
    Fossella, Frank V.
    Byers, Lauren Averett
    Zhang, Jianjun
    Gay, Carl Michael
    Tu, Janet Chen
    Pozadzides, Jenny Vu
    Tran, Hai T.
    Lu, Charles
    Feng, Lei
    Spelman, Amy R.
    Blumenschein, George R.
    Tsao, Anne S.
    Heymach, John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naive EGFR-Mutated Metastatic Non-Small Cell Lung
    Padda, S.
    Reckamp, K.
    Koczywas, M.
    Neal, J.
    Kawashima, J.
    Kong, S.
    Xin, Y.
    Huang, D.
    Wakelee, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2142 - S2143
  • [8] A Phase 1b Study of Demcizumab Plus Pemetrexed and Carboplatin in Patients with 1st Line Non-Small Cell Lung Cancer (NSCLC)
    McKeage, M.
    Kotasek, D.
    Millward, M.
    Markman, B.
    Jameson, M.
    Hidalgo, M.
    Harris, D.
    Stagg, R.
    Dupont, J.
    Hughes, B.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : 183 - 184
  • [9] A Phase 1b/2 Study of Atezolizumab With or Without Daratumumab in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Pillai, R.
    Ramalingam, S.
    Paz-Ares, L.
    Thayu, M.
    Watson, P.
    Reck, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2288 - S2288
  • [10] Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases
    Kaneda, Hiroyasu
    Sawa, Kenji
    Daga, Haruko
    Okada, Asuka
    Nakatani, Yuki
    Atagi, Shinji
    Okishio, Kyoichi
    Tani, Yoko
    Matsumoto, Yoshiya
    Ogawa, Koichi
    Nakahama, Kenji
    Izumi, Motohiro
    Mitsuoka, Shigeki
    Kawaguchi, Tomoya
    [J]. INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1598 - 1603
12345